MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Inhibiting transgene expression with a tissue-specific microRNA target ameliorates AAV vector toxicity in NHPs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These results further suggest that the differences in signalling observed between CAG and hAAT-carrying vectors in vitro are due to expression of the transgene similar to what has been reported in the context of DRG toxicity 38 .”
From AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain (2025) · cites this paper as [38]
In the citing paper
“Previous work has suggested a role for transgene over-expression in DRG toxicity 38 .”
From AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain (2025) · cites this paper as [38]
In the citing paper
“possibility of alternative, non-immune-mediated toxicity such as dorsal root ganglion toxicity with AAV9 (110)”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [110]
In the citing paper
“For example, AAV-mediated gene delivery into the CNS of pigs or non-human primates causes dorsal root ganglion toxicity that is alleviated by reducing or deleting transgene expression.38,39,66”
From An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission (2024) · cites this paper as [39]
In the citing paper
“Despite an overall strong safety profile, AAV-mediated gene delivery has been associated with neurotoxicity in specific cell populations, some of which can be attributed to the overexpressed transgene.”
From An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission (2024) · cites this paper as [39]
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-P., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,498
Self-citationClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“At the turn of the century, researchers found a family of endogenous AAVs that, as vectors, achieved much higher transduction efficiencies while retaining favorable safety profiles (2).”
BackgroundSelf-citationDistribution of miRNA expression across human tissues
Ludwig, N., Leidinger, P., Becker, K., Backes, C., Fehlmann, T., Pallasch, C., Rheinheimer, S., Meder, B., Stähler, C., Meese, E., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw116 · Cited by 968 · cited 1×
“Under normal conditions, expression of this complex is largely restricted to neurons of the olfactory epithelium, ear, retina, and DRG as demonstrated in zebrafish (23), mouse (24–26), rat (27), and human tissues (24, 28).”
BackgroundHinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
Self-citationHoggan, M. D., Blacklow, N. R., & Rowe, W. P. (1966) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.55.6.1467 · Cited by 536
Brown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Nature Medicine · doi:10.1038/nm1398 · Cited by 484 · cited 1×
“We used an approach previously deployed for restricting lentiviral vector expression in hematopoietic-derived cells (20) or detargeting the liver, heart, or muscle after AAV-mediated gene transfer (21, 22).”
Method
Research works printed but not linked: 2
- Pfizer (2019); https://investors.pfizer.com/investor-news/press-release-details/2019/Pfizer-Presents-Initial-Clinical-Data-on-Phase-1b-Gene-Therapy-Study-for-Duchenne-Muscular-Dystrophy-DMD/default.aspx.
- V. Kumar A. K. Abbas J. C. Aster Robbins and Cotran Pathologic Basis of Disease (Elsevier Saunders Philadelphia 2015) pp. 31–68.
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“443 Another potential mitigating strategy is to target the peptide processing and MHC presentation pathway.”
BackgroundGoertsen, D., Flytzanis, N. C., Goeden, N., Chuapoco, M. R., Cummins, A., Chen, Y., Fan, Y., Zhang, Q., Sharma, J., Duan, Y., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00969-4 · Cited by 420
Immunogenicity and toxicity of AAV gene therapy
Ertl, H. C. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975803 · Cited by 402
AAV-based in vivo gene therapy for neurological disorders
Ling, Q., Herstine, J. A., Bradbury, A., & Gray, S. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00766-7 · Cited by 197
Gene therapy for ALS: A review
Amado, D. A., & Davidson, B. L. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.008 · Cited by 184
“Recent studies successfully used DRG-specific miRNAs to downregulate transgene expression in these cells while preserving intended CNS transduction, an efficient detargeting strategy that can be employed across any AAV-based therapeutic.(126) Finally, one notable study used a novel subpial delivery method, administeri…”
MethodrAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
“Notably, researchers have developed a potential strategy to reduce the DRG toxicity by silencing the transgene expression in DRG via microRNA (69).”
BackgroundAddressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’
Kishimoto, T. K., & Samulski, R. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2060737 · Cited by 152
“Improvements in promoter and enhancer design could also improve efficacy at lower doses, although the potential risks of HCC associated with strong promoters and DRG toxicity with transgene overexpression must be considered [16,21].”
BackgroundAdeno-Associated Virus Toolkit to Target Diverse Brain Cells
Challis, R. C., Ravindra Kumar, S., Chen, X., Goertsen, D., Coughlin, G. M., Hori, A. M., Chuapoco, M. R., Otis, T. S., Miles, T. F., & Gradinaru, V. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-111020-100834 · Cited by 148
“Understanding the mechanisms underlying toxicity [e.g., transgene overexpression (Hordeaux et al. 2020b, Van Alstyne et al. 2021) or immunodetection of the AAV genome (Suriano et al. 2021)], and how they may manifest clinically, will inform future therapies.”
BackgroundInfluentialAdeno-Associated Virus Gene Therapy for Hemophilia
Samelson‐Jones, B. J., & George, L. A. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033013 · Cited by 150
Current clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 162
AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
“Transgene overexpression under a strong enhancer/promoter combination may also have contributed to AEs causing deleterious effects on normal cellular function and cellular stress.(92,93) Reducing the dose by improving the rAAV vector transduction efficiency(97) may have the potential to circumvent such high-dose AEs a…”
BackgroundAndari, J. E., Renaud-Gabardos, E., Tulalamba, W., Weinmann, J., Mangin, L., Pham, Q. H., Hille, S. S., Bennett, A. D., Attebi, E., Bourges, E., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn4704 · Cited by 102
Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
Gene therapy for liver diseases — progress and challenges
Zabaleta, N., Unzu, C., Weber, N. D., & González‐Aseguinolaza, G. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00729-0 · Cited by 80
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
Chen, X., Lim, D. A., Lawlor, M. W., Dimmock, D., Vite, C. H., Lester, T. L., Tavakkoli, F., Sadhu, C., Prasad, S., & Gray, S. J. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.163 · Cited by 72
“84,85 As DRG toxicity appears to be related to the level of transgene expressed, experimental efforts to mitigate this toxicity have focused on strategies to prevent or lessen transgene expression in DRGs, 78 rather than efforts to affect vector biodistribution to DRGs.”
Palmieri, M., Pozzer, D., & Landsberger, N. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1172805 · Cited by 72
“, 2021), microRNA target sites (Hordeaux et al., 2020) and viral capsid variants (Matsuzaki et al.”
BackgroundGross, D., Tedesco, N., Leborgne, C., & Ronzitti, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857276 · Cited by 65
“This neuronal toxicity was not prevented by conventional steroid regimens and was dependent on overabundance of the transgene product and subsequent activation of cellular stress pathway (63).”
BackgroundAAV Engineering for Improving Tropism to the Central Nervous System
Ghauri, M. S., & Ou, L. (2023) · Biology · doi:10.3390/biology12020186 · Cited by 73
“A method to address this issue was by including a miR-142 element to minimize transgene expression in DRG [95].”
MethodInfluentialGene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development
Massaro, G., Geard, A. F., Liu, W., Coombe-Tennant, O., Waddington, S. N., Baruteau, J., Gissen, P., & Rahim, A. A. (2021) · Biomolecules · doi:10.3390/biom11040611 · Cited by 68
Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
Stanton, A. C., Lagerborg, K. A., Tellez, L., Krunnfusz, A., King, E. M., Ye, S. H., Solomon, I. H., Tabebordbar, M., & Sabeti, P. C. (2022) · Med · doi:10.1016/j.medj.2022.11.002 · Cited by 71
Inflamma-MicroRNAs in Alzheimer’s Disease: From Disease Pathogenesis to Therapeutic Potentials
Liang, Y., & Wang, L. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.785433 · Cited by 58
Identification and targeting of a unique Na V 1.7 domain driving chronic pain
Gómez, K., Stratton, H. J., Duran, P., Loya‐López, S., Tang, C. W., Calderón‐Rivera, A., François‐Moutal, L., Khanna, M., Madura, C. L., Luo, S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2217800120 · Cited by 55
In vivo base editing extends lifespan of a humanized mouse model of prion disease
An, M., Davis, J. R., Levy, J. M., Serack, F. E., Harvey, J. W., Brauer, P. P., Pirtle, C. P., Berríos, K. N., Newby, G. A., Yeh, W.-H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03466-w · Cited by 64
“Transgene overexpression in dorsal root ganglion (DRG) and liver has been linked to toxicity with high-dose AAV treatment 49,50 .”
Spatial transcriptomics for profiling the tropism of viral vectors in tissues
Jang, M. J., Coughlin, G. M., Jackson, C. R., Chen, X., Chuapoco, M. R., Vendemiatti, J., Wang, A. Z., & Gradinaru, V. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01648-w · Cited by 71
“For example, miRNA TS has been shown to have potential use for cell-type-specific transgene expression and mitigation of AAV toxicity for clinical applications owing to its ability to suppress transgene expression in the cells or tissue where the respective miRNA is highly expressed 26,70,71 .”
Optimization of AAV vectors to target persistent viral reservoirs
Colón-Thillet, R., Jerome, K. R., & Stone, D. (2021) · Virology Journal · doi:10.1186/s12985-021-01555-7 · Cited by 50
“However, a recent study suggests that AAV-associated DRG toxicity can be reduced when a microRNA target is included in the vector backbone that selectively knocks down transgene expression in the DRG [170].”
BackgroundMuhuri, M., Zhan, W., Maeda, Y., Li, J., Lotun, A., Chen, J., Sylvia, K., Dasgupta, I., Arjomandnejad, M., Nixon, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674242 · Cited by 50
Chen, X., Dong, T., Hu, Y., Pace, R. D., Mattera, R., Eberhardt, K., Ziegler, M., Pirovolakis, T., Şahin, M., Bonifacino, J. S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164575 · Cited by 49
“In conclusion, i.t. administration of AAV9/AP4M1 by a single i.t. injection in cynomolgus monkeys was well tolerated at 8.4 × 1013 vg. Adverse findings at 1.68 × 1014 vg included axonal or neuronal degeneration observed microscopically in the spinal cord (including the injection site), lumbar DRG, dorsal nerve roots,…”
InfluentialTherapies in preclinical and clinical development for Angelman syndrome
Markati, T., Duis, J. B., & Servais, L. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1939674 · Cited by 49
Chen, X., Dong, T., Hu, Y.-H., Shaffo, F. C., Belur, N. R., Mazzulli, J., & Gray, S. (2022) · Journal of Clinical Investigation · doi:10.1172/jci146286 · Cited by 40
“An identified risk of inflammatory damage to DRG is an emerging safety concern of CNS-directed AAV GT that has been reported from recent nonclinical studies in NHPs as well as piglets (54–56).”
InfluentialThe curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 52
Muscle‐directed gene therapy corrects Pompe disease and uncovers species‐specific GAA immunogenicity
Eggers, M., Vannoy, C. H., Huang, J., Purushothaman, P., Brassard, J. A., Fonck, C., Meng, H., Prom, M. J., Lawlor, M. W., Cunningham, J. J., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202113968 · Cited by 43
Parrett, B. J., Yamaoka, S., & Barry, M. A. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101402 · Cited by 46
Campos, L., Arokiaraj, C. M., Chuapoco, M. R., Chen, X., Goeden, N., Gradinaru, V., & Fox, A. S. (2023) · Current Research in Neurobiology · doi:10.1016/j.crneur.2023.100086 · Cited by 44
Adeno-associated virus vectors and neurotoxicity—lessons from preclinical and human studies
Stone, D., Aubert, M., & Jerome, K. R. (2023) · Gene Therapy · doi:10.1038/s41434-023-00405-1 · Cited by 44
“…AAV-associated toxicity within the PNS and spinal cord may be mediated by overexpression of the transgene-derived mRNA or protein rather than the capsid or vector DNA, based on observations in NHP that neuronal degeneration occurs preferentially in cells with the highest transgene expression [8].”
InfluentialFader, K. A., Pardo, I. D. R., Kovi, R. C., Somps, C. J., Wang, H. H., Vaidya, V. S., Ramaiah, S. K., & Sirivelu, M. P. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.017 · Cited by 41
“Dose and age at injection were found to significantly affect the severity of neuronal lesions, while sex had no impact (Hordeaux et al., 2020a).”
BackgroundInfluentialUnderstanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 47
“…of T cell responses and studies in the presence of immunosuppressive drugs do not support a clear role of T cell-mediated immunity, 41,43 but studies suggest a correlation between overabundance of the transgene product and neuron loss, 42 as reported also by Henry et al., at the 2023 ASGT meeting.”
Xie, Q., Chen, X., Ma, H., Zhu, Y., Ma, Y., Jalinous, L., Cox, G. F., Weaver, F., Yang, J., Kennedy, Z., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00037-x · Cited by 44
“Subsequent investigations showed that DRG toxicity is dependent upon transgene expression and AAV dose (Buss et al, 2022; Hordeaux et al, 2020b; Palazzi et al, 2022; Tukov et al, 2022).”
Self-citationErtl, H. C. J. (2023) · Drugs · doi:10.1007/s40265-023-01836-1 · Cited by 43
Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level
Kang, D. D., Marks, A. R., Morlà‐Folch, J., Dong, Y., Brown, B. D., & Teunissen, A. J. P. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01511-8 · Cited by 51
“…has shown that miRTs can suppress vector expression in many cell types 147,150–152 , including hepatocytes with miR-122T 147,153–155 , HSCs and endothelial cells with miR-126T 147,156 , neurons with miR-124T 157–161 , myocytes with miR-206T 162 , and B and T cells with miR-181T 147,163 .”
Routes of administration for adeno-associated viruses carrying gene therapies for brain diseases
Zhou, K., Han, J., Wang, Y., Zhang, Y., & Zhu, C. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.988914 · Cited by 46
“Furthermore, inserting an miR183 biding site in rAAVs can prevent dorsal root ganglion toxicity (Hordeaux et al., 2020).”
BackgroundMarcó, S., Haurigot, V., Jaén, M. L., Ribera, A., Sánchez, V., Molas, M., Garcia, M., León, X., Roca, C., Sánchez, X., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.017 · Cited by 45
AAV vectors trigger DNA damage responses and STING-dependent inflammation in human CNS cells
Costa-Verdera, H., Meneghini, V., Fitzpatrick, Z., Alezz, M. A., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2024) · doi:10.21203/rs.3.rs-4171795/v1 · Cited by 32
Costa-Verdera, H., Meneghini, V., Fitzpatrick, Z., Abou Alezz, M., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58778-3 · Cited by 32
Youssef, E. M., Weddle, K., Zimmerman, L., & Palmer, D. (2025) · Drug Safety · doi:10.1007/s40264-025-01596-9 · Cited by 42
“Reports of TMA have contributed to updated FDA product labeling and refined PVG guidance, underscoring the critical role of post-marketing case data in shaping risk management strategies [158].”
Beharry, A. W., Gong, Y., Kim, J. C., Hanlon, K. S., Nammour, J., Hieber, K., Eichler, F., Cheng, M. L., Stemmer-Rachamimov, A. O., Stanković, K. M., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.069 · Cited by 34
“…DRG. 14 Since AAV-F mediates transduction efficiency on par or higher than AAV9 in the spinal cord, and lower percentage of DRG transduction, the combination of this capsid with posttranscriptional reduction in transgene expression using microRNA seed sequences, 22 may help mitigate this toxicity.”
Gene therapy for Parkinson's disease: trials and technical advances
Winston, G. M., Kharas, N., Svenningsson, P., Jha, A., & Kaplitt, M. G. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00125-5 · Cited by 31
Fakhiri, J., & Grimm, D. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.005 · Cited by 30
The use of viral vectors to promote repair after spinal cord injury
Islam, A., & Tom, V. J. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114102 · Cited by 30
Gene editing for latent herpes simplex virus infection reduces viral load and shedding in vivo
Aubert, M., Haick, A. K., Strongin, D. E., Klouser, L. M., Loprieno, M. A., Stensland, L., Santo, T. K., Huang, M.-L. W., Hyrien, O., Stone, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47940-y · Cited by 30
“The causative mechanism of such injury remains unclear; among the current leading hypotheses are saturation of neural protein-folding capacity 35 and TLR9-mediated recognition of vector or transgene RNA 36 .”
In vivo applications and toxicities of AAV-based gene therapies in rare diseases
Zhao, Q., Peng, H., Ma, Y., Yuan, H., & Jiang, H. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03893-z · Cited by 33
“One study revealed that adding microRNA183 targets to the vector reduced transgene expression and toxicity in DRG neurons without affecting transduction in other parts of the primate brain [93].”
Chen, S. K., Hawley, Z. C. E., Zavodszky, M. I., Hana, S., Ferretti, D., Grubor, B., Hawes, M. C., Xu, S., Hamann, S., Marsh, G., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102057 · Cited by 28
Hutt, J. A., Assaf, B. T., Bolon, B. N., Cavagnaro, J. A., Galbreath, E. J., Grubor, B., Kattenhorn, L. M., Romeike, A., & Whiteley, L. O. (2021) · Toxicologic Pathology · doi:10.1177/01926233211041962 · Cited by 28
Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders
Davidson, B. L., Gao, G., Berry‐Kravis, E., Bradbury, A. M., Bönnemann, C. G., Buxbaum, J. D., Corcoran, G. R., Gray, S. J., Gray‐Edwards, H. L., Kleiman, R. J., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.014 · Cited by 31
“Additional measures, such as engineering AAVs(30) to avoid DRGs or reducing expressing within DRGs are under development.(46)”
BackgroundJohnson, E. W., Sutherland, J. J., Meseck, E. K., McElroy, C., Chand, D. H., Tukov, F. F., Hudry, E., & Penraat, K. A. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.12.012 · Cited by 30
“No increases in NfL were observed within a 28-day post-dose observation period after administration of empty AAV9 capsid and scAAV9 containing a promoter-less transgene, consistent with the subsequent lack of DRG degeneration, necrosis, and/or loss, supporting the supposition that the pathogenesis of the AAV-related D…”
BackgroundClinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 31
Hawley, Z. C. E., Pardo, I. D. R., Cao, S., Zavodszky, M. I., Casey, F., Ferber, K. L., Luo, Y., Hana, S., Chen, S. K., Doherty, J., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.029 · Cited by 27
AAV- based vector improvements unrelated to capsid protein modification
Shitik, E. M., Shalik, I. K., & Yudkin, D. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1106085 · Cited by 30
“Compared to the unmodified vectors, the vectors containing miR-183 binding sites in the 3UTR reduced dorsal root ganglion toxicity at a statistically significant level (88).”
BackgroundRNA therapies for CNS diseases
Francesco, V. D., Chua, A. J. K., Huang, D., D’souza, A. A., Yang, A., Bleier, B. S., & Amiji, M. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115283 · Cited by 27
Ross, P. D., Gadalla, K. K. E., Thomson, S. R., Selfridge, J., Bahey, N. G., Benito, J., Burstein, S. R., McMinn, R., Bolon, B. N., Hector, R. D., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq3614 · Cited by 26
Hordeaux, J., Ramezani, A., Tuske, S., Mehta, N., Song, C., Lynch, A., Lupino, K., Chichester, J. A., Buza, E. L., Dyer, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094279 · Cited by 23
Self-citationRescue of a familial dysautonomia mouse model by AAV9-Exon-specific U1 snRNA
Romano, G., Riccardi, F., Bussani, E., Vodret, S., Licastro, D., Ragone, I., Ronzitti, G., Morini, E., Slaugenhaupt, S., & Pagani, F. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.07.004 · Cited by 24
Gene therapies for mucopolysaccharidoses
Rossi, A., & Brunetti‐Pierri, N. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12626 · Cited by 25
“57,58 Moreover, there is evidence that DRG toxicity might be related to transgene overexpression.”
BackgroundHemophilia gene therapy: ushering in a new treatment paradigm?
George, L. A. (2021) · Hematology · doi:10.1182/hematology.2021000254 · Cited by 25
Gardin, A., & Ronzitti, G. (2023) · Archives de Pédiatrie · doi:10.1016/s0929-693x(23)00227-0 · Cited by 25
Suriano, C. M., Kumar, N., Verpeut, J. L., Ma, J., Jung, C., Dunn, C. E., Carvajal, B. V., Nguyen, A. V., & Boulanger, L. M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.036 · Cited by 21
“38,39,66 Additionally, overexpression of SMN1 in a spinal muscular atrophy mouse model causes a toxic gain of function.”
Lüscher, C., Emiliani, V., Farahany, N. A., Gittis, A. H., Gradinaru, V., High, K. A., Roska, B., Sahel, J., Yizhar, O., Zeng, H., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02097-9 · Cited by 30
“…hepatocytes (which express the transgene) toward resident macrophage Kupffer cells (which destroy the vector without expressing the transgene) 97 , miRNA target sites could also be incorporated into the payload to decrease toxicity associated with liver or dorsal root ganglion expression 96,98,99 .”
Improving clinical trial readiness to accelerate development of new therapeutics for Rett syndrome
Leonard, H., Gold, W. A., Samaco, R. C., Şahin, M., Benke, T. A., & Downs, J. A. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02240-w · Cited by 21
Breaching the blood-brain barrier: AAV triggers dose-dependent toxicity in the brain
Stone, D., Aubert, M., & Jerome, K. R. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.09.001 · Cited by 23
“The mechanisms by which AAV triggers toxicity and/or cell death in nervous tissues are poorly understood, although immune-mediated mechanisms and apoptosis following activation of the unfolded protein response have been implicated in the death of AAV transduced neuronswithin the dorsal root ganglion (DRG).(5) In the b…”
BackgroundEngineering novel adeno-associated viruses (AAVs) for improved delivery in the nervous system
Carneiro, A. D., & Schaffer, D. V. (2024) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2024.102532 · Cited by 22
Miyake, N., Miyake, K., Sakai, A., Yamamoto, M., Suzuki, H., & Shimada, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-99979-2 · Cited by 18
Duan, D., & Herzog, R. W. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.067 · Cited by 24
Morris, J. A., Boshoff, C. H., Schor, N. F., Wong, L. M., Gao, G., & Davidson, B. L. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.010 · Cited by 16
Kofoed, R. H., Noseworthy, K., Wu, K., Sivadas, S., Stanek, L. M., Elmer, B. M., Hynynen, K., Shihabuddin, L. S., & Aubert, I. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.011 · Cited by 18
“This degeneration is likely caused by high levels of transgene expression and can be prevented by reducing transgene expression specifically in dorsal root ganglions, but not by conventional immunosuppression.(59) To date, such dorsal root ganglion pathology in non-human primates has not been associated with any clini…”
BackgroundEliminating Panglossian thinking in development of AAV therapeutics
Kaczmarek, R., Pierce, G. F., Noone, D., O’Mahony, B., Page, D., & Skinner, M. W. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.025 · Cited by 14
Gene therapy for neurotransmitter‐related disorders
Chu, W. S., Ng, J., Waddington, S. N., & Kurian, M. A. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12697 · Cited by 16
Hanlon, K. S., Cheng, M. L., Ferrer, R. M., Ryu, J. R., Lee, B., de la Cruz, D., Patel, N. J., Espinoza, P., Santoscoy, M. C., Gong, Y., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.040 · Cited by 14
Blahetek, G., Mayer, C. A., Zuber, J. A., Lenter, M., & Strobel, B. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101280 · Cited by 16
“38 A strategy to conditionally induce AAV-mediated transgene expression by shRNAs was recently demonstrated by Subramanian et al., who generated a self-silencing AAV transgene expression cassette.”
BackgroundRan, G., Feng, X.-L., Xie, Y., Zheng, Q., Guo, P., Yang, M., Feng, Y., Ling, C., Zhu, L., & Chen, Z. (2021) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2021.09.004 · Cited by 14
Sun, J., Zhang, X., Cong, Q., Chen, D., Yi, Z., Huang, H., Wang, C., Li, M., Zeng, R., Liu, Y., et al. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.03.012 · Cited by 14
Self-citationChou, S.-W., Mortberg, M. A., Marlen, K., Ojala, D. S., Parman, T., Howard, M., DeSouza-Lenz, K., Lian, Y., Mehrabian, M., Tiffany, M. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.05.636713 · Cited by 17
Gene therapy – are we ready now?
Kaczmarek, R. (2022) · Haemophilia · doi:10.1111/hae.14530 · Cited by 15
Santoscoy, M. C., Espinoza, P., de la Cruz, D., Mahamdeh, M., Starr, J. R., Patel, N. J., & Maguire, C. A. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.05.001 · Cited by 15
“Furthermore data mining of miRNA sequences enriched in neuronal subtypes compared to cholinergic neurons may be used to incorporate the corresponding sequences into the AAV expression cassette to knock down transgene mRNA in these other neurons similar to what has been done with mIR183 de-targeting of AAV expression i…”
MethodSalegio, E. A., Hancock, K., & Korszen, S. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1248271 · Cited by 12
De, B. P., Rosenberg, J. B., Selvan, N., Wilson, I., Yusufzai, N., Greco, A., Kaminsky, S. M., Heier, L., Arbona, R. J. R., Miranda, I. C., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.067 · Cited by 14
“The DRG abnormalities in terms of observed le-Figure sions were similar to those previously attributed to administration of AAV vectors to NHPs, 35,38,42,48–50 but only in one animal.”
Bolon, B. N., Buza, E. L., Galbreath, E. J., Wicks, J. R., Cargnin, F., & Hordeaux, J. (2024) · Toxicologic Pathology · doi:10.1177/01926233241300314 · Cited by 13
“14,30,45,55 However, the AAV pattern depends on many parameters.”
Self-citationAeran, R., Tanenhaus, A., Sears, S. M. S., Moerke, N. J., Miller, A., Artur, C., Bouhlal, Y., Bove, P. F., de Arce, A. J. D., Shimizu, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.011 · Cited by 13
“44–46 Severity gradings pertaining to decreased neuronal cellularity or neuronal necrosis within DRG (any severity grade ≥ 1 on a scale of from 1 [minimal] to 5 [severe]) or neuronal degeneration within the SC (severity grade ≥ 2) were considered potentially adverse, given the limited neuronal…”
Martino, R. A., Wang, Q., Xu, H. Y., Hu, G. B., Bell, P. L., Arroyo, E. J., Sims, J. J., & Wilson, J. M. (2023) · Journal of Virology · doi:10.1128/jvi.00174-23 · Cited by 13
Self-citationBennet, B. M., Pardo, I. D. R., Assaf, B. T., Buza, E. L., Cramer, S. D., Crawford, L. K., Engelhardt, J. A., Galbreath, E. J., Grubor, B., Morrison, J. P., et al. (2023) · Toxicologic Pathology · doi:10.1177/01926233231213851 · Cited by 12
“60,185 AAV-mediated transgene overexpression with ensuing unfolded protein response (UPR)-mediated cell death is currently considered the leading hypothesis of primary AAV-associated DRG findings in NHPs. 99,100 In a recent meta-analysis, the severity of AAV-associated findings in the sensory ganglia of NHPs was tight…”
InfluentialSelf-citationMinno, G. D., Miesbach, W., Castaman, G., & Peyvandi, F. (2024) · Haematologica · doi:10.3324/haematol.2023.284622 · Cited by 21
RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes
Subramanian, M. P., McIninch, J., Zlatev, I., Schlegel, M. K., Kaittanis, C., Nguyen, T. M., Agarwal, S., Racie, T., Alvarado, M. A., Wassarman, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37774-5 · Cited by 12
Peripherally delivered Adeno-associated viral vectors for spinal cord injury repair
Sydney-Smith, J. D., Spejo, A. B., Warren, P. M., & Moon, L. D. F. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113945 · Cited by 12
Sher, E. K., Džidić-Krivić, A., Karahmet, A., Beća-Zećo, M., Farhat, E. K., Softič, A., & Sher, F. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102901 · Cited by 10
Genetic editing of primary human dorsal root ganglion neurons using CRISPR-Cas9
Palomino, S. M., Gabriel, K. A., Mwirigi, J. M., Cervantes, A. M., Horton, P., Funk, G. A., Moutal, A., Martin, L. F., Khanna, R., Price, T. J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-91153-2 · Cited by 11
“Our work was motivated by the need for a genome editing technique for discovery work utilizing human primary neurons, and for pre-clinical application in pain studies.”
Genetic Approaches for Neural Circuits Dissection in Non-human Primates
Li, L., & Liu, Z. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01067-0 · Cited by 10
Cross-species RNAi therapy via AAV delivery alleviates neuropathic pain by targeting GCH1
Chang, H., Lee, K. J., Park, M., Woo, H., Kim, J. H., Kang, I. K., Park, H., Chon, C. H., Lee, H., & Jung, H. H. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00511 · Cited by 8
“Delivering AAV into the central nervous system via the blood or cerebral spinal fl uid has been reported to be associated with DRG toxicity due to apoptosis of neural cells [37].”
VWA3A-derived ependyma promoter drives increased therapeutic protein secretion into the CSF
Carrell, E. M., Chen, Y. H., Ranum, P. T., Coffin, S. L., Singh, L. N., Tecedor, L., Keiser, M. S., Hudry, E., Hyman, B. T., & Davidson, B. L. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.07.016 · Cited by 10
Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?
Tang, A., & Yokota, T. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2447072 · Cited by 10
Metadata
- Authors
- Hordeaux, J., Buza, E. L., Jeffrey, B., Song, C., Jahan, T., Yuan, Y., Zhu, Y., Bell, P., Li, M., Chichester, J. A., Calcedo, R., & Wilson, J. M.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Wilson, James M.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2020-11-11
- Volume
- 12
- Issue
- 569
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3104217413
- Cited by
- 174
- References
- 39
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 32 · 2023: 37 · 2022: 26 · 2021: 25 · 2020: 1
- FWCI
- 13.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania Gene Therapy Program
- Orphan Disease Center (MPS-19-001-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- adeno-associated virus vectors, microRNA-183, transgene expression regulation, 3' untranslated region, non-human primates, central nervous system gene therapy, neurotoxicity, cisterna magna injection, steroid immunosuppression
- MeSH terms
- Dependovirus, Animals, Ganglia, Spinal, Genetic Vectors, Primates, Transduction, Genetic, Gene Transfer Techniques, Transgenes, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.